{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T06:34:06Z","timestamp":1764570846921,"version":"build-2065373602"},"reference-count":92,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seminarsinnephrology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.semnephrol.2018.12.006","type":"journal-article","created":{"date-parts":[[2019,2,28]],"date-time":"2019-02-28T03:05:58Z","timestamp":1551323158000},"page":"176-189","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Modeling Exposure to Understand and Predict Kidney Injury"],"prefix":"10.1016","volume":"39","author":[{"given":"Zhenhong","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ciaran","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iain","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avijit","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Litchfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tristan S.","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semnephrol.2018.12.006_bib0001","first-page":"510","article-title":"Die dritte defension wegen des schreibens der neuen rezepte","volume":"1965","author":"Paracelsus","year":"1538","journal-title":"Septem Defensiones"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0002","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1002\/hep.22272","article-title":"Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals","volume":"47","author":"Lammert","year":"2008","journal-title":"Hepatology (Baltimore, Md)"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0003","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/hep.26208","article-title":"High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury","volume":"58","author":"Chen","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0004","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/hep.23317","article-title":"Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events","volume":"51","author":"Lammert","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0005","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/2071301a0","article-title":"Blood levels of drug at the equilibrium state after multiple dosing","volume":"207","author":"Wagner","year":"1965","journal-title":"Nature"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0006","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/phar.2087","article-title":"Validation and clinical utility of the hERG IC50:Cmax ratio to determine the risk of drug-induced Torsades de pointes: a meta-analysis","volume":"38","author":"Lehmann","year":"2018","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0007","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1021\/acs.chemrestox.5b00410","article-title":"Reactive metabolites: current and emerging risk and hazard assessments","volume":"29","author":"Thompson","year":"2016","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0008","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.tiv.2014.10.019","article-title":"Intracellular concentrations determine the cytotoxicity of adefovir, cidofovir and tenofovir","volume":"29","author":"Zhang","year":"2015","journal-title":"Toxicol In Vitro"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0009","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1039\/C7MT00271H","article-title":"On the toxicity and transport mechanisms of cisplatin in kidney tissues in comparison to a gold-based cytotoxic agent","volume":"9","author":"Spreckelmeyer","year":"2017","journal-title":"Metallomics"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0010","doi-asserted-by":"crossref","first-page":"5573","DOI":"10.1128\/AAC.00907-16","article-title":"Organic cation transporter 2 overexpression may confer an increased risk of gentamicin-induced nephrotoxicity","volume":"60","author":"Gai","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0011","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1111\/bph.13537","article-title":"Role of OCT2 and MATE1 in renal disposition and toxicity of nitidine chloride","volume":"173","author":"Li","year":"2016","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0012","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1517\/14740338.7.2.147","article-title":"Drug-induced crystal nephropathy: an update","volume":"7","author":"Yarlagadda","year":"2008","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0013","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1007\/s00467-011-1843-8","article-title":"Human nephron number: implications for health and disease","volume":"26","author":"Bertram","year":"2011","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0014","series-title":"xPharm: the comprehensive pharmacology reference","first-page":"1","article-title":"Glomerular filtration","author":"Carroll","year":"2007"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0015","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1155\/2012\/481520","article-title":"Mechanisms of glomerular albumin filtration and tubular reabsorption","volume":"2012","author":"Tojo","year":"2012","journal-title":"Int J Nephrol"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0016","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/S0025-7125(16)32106-X","article-title":"Effect of disease states on plasma protein binding of drugs","volume":"58","author":"Reidenberg","year":"1974","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0017","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0018","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1681\/ASN.2007020199","article-title":"Evaluation of the modification of diet in renal disease study equation in a large diverse population","volume":"18","author":"Stevens","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0019","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0020","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1152\/ajplegacy.1960.198.3.581","article-title":"Localization of urine acidification in the mammalian kidney","volume":"198","author":"Gottschalk","year":"1960","journal-title":"Am J Physiol"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0021","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejps.2017.11.001","article-title":"Renal organic anion transporters in drug-drug interactions and diseases","volume":"112","author":"Huo","year":"2018","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0022","doi-asserted-by":"crossref","first-page":"F1069","DOI":"10.1152\/ajprenal.00646.2011","article-title":"Basolateral membrane K+ channels in renal epithelial cells","volume":"302","author":"Hamilton","year":"2012","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0023","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.2215\/CJN.08580813","article-title":"Regulation of potassium homeostasis","volume":"10","author":"Palmer","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0024","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/ki.1976.14","article-title":"Electrical phenomena in the nephron","volume":"9","author":"Boulpaep","year":"1976","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0025","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1002\/j.2040-4603.2011.tb00386.x","article-title":"Renal transport of organic anions and cations","volume":"1","author":"Pelis","year":"2011","journal-title":"Compr Physiol"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0026","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1152\/physrev.00042.2012","article-title":"Renal autoregulation in health and disease","volume":"95","author":"Carlstrom","year":"2015","journal-title":"Physiol Rev"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0027","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/j.1742-4658.2006.05614.x","article-title":"Modulation of Ca2+ entry and plasma membrane potential by human TRPM4b","volume":"274","author":"Fliegert","year":"2007","journal-title":"FEBS J"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0028","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s40262-017-0506-8","article-title":"Renal drug transporters and drug interactions","volume":"56","author":"Ivanyuk","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0029","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3028","article-title":"Membrane transporters in drug development","volume":"9","author":"Giacomini","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0030","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.apsb.2016.07.013","article-title":"Renal drug transporters and their significance in drug\u2013drug interactions","volume":"6","author":"Yin","year":"2016","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0031","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.kint.2015.11.007","article-title":"Megalin and cubilin in proximal tubule protein reabsorption: from experimental models to human disease","volume":"89","author":"Nielsen","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0032","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.addr.2017.01.005","article-title":"Xenobiotic transporters and kidney injury","volume":"116","author":"George","year":"2017","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0033","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev-physiol-022516-034234","article-title":"Receptor-mediated endocytosis in the proximal tubule","volume":"79","author":"Eshbach","year":"2017","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0034","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejps.2016.03.020","article-title":"Metformin and cimetidine: physiologically based pharmacokinetic modelling to investigate transporter mediated drug-drug interactions","volume":"88","author":"Burt","year":"2016","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0035","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1124\/dmd.118.082313","article-title":"The importance of incorporating OCT2 plasma membrane expression and membrane potential in IVIVE of metformin renal secretory clearance","volume":"46","author":"Kumar","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0036","doi-asserted-by":"crossref","first-page":"F467","DOI":"10.1152\/ajprenal.00628.2016","article-title":"Characterization of the transport activity of SGLT2\/MAP17, the renal low-affinity Na(+)-glucose cotransporter","volume":"313","author":"Coady","year":"2017","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0037","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1038\/ki.2009.87","article-title":"Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications","volume":"75","author":"Bakris","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0038","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/ki.1980.181","article-title":"Metabolism of drugs by the kidney","volume":"18","author":"Anders","year":"1980","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0039","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0031-6997(24)01351-6","article-title":"Renal drug metabolism","volume":"50","author":"Lohr","year":"1998","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0040","series-title":"Transporters in drug development: discovery, optimization, clinical study and regulation","first-page":"155","article-title":"Accounting for transporters in renal clearance: towards a mechanistic kidney model (Mech KiM)","author":"Neuhoff","year":"2013"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0041","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ejps.2016.03.018","article-title":"Novel minimal physiologically-based model for the prediction of passive tubular reabsorption and renal excretion clearance","volume":"94","author":"Scotcher","year":"2016","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0042","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/psp4.12321","article-title":"Development of a dynamic physiologically based mechanistic kidney model to predict renal clearance","volume":"7","author":"Huang","year":"2018","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0043","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/bcp.12234","article-title":"Combining the \u2018bottom up\u2019 and \u2018top down\u2019 approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data","volume":"79","author":"Tsamandouras","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0044","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40262-013-0117-y","article-title":"Towards quantitation of the effects of renal impairment and probenecid inhibition on kidney uptake and efflux transporters, using physiologically based pharmacokinetic modelling and simulations","volume":"53","author":"Hsu","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0045","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1124\/dmd.114.059618","article-title":"Prediction of renal transporter mediated drug-drug interactions for pemetrexed using physiologically based pharmacokinetic modeling","volume":"43","author":"Posada","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0046","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1124\/jpet.116.237438","article-title":"Delineating the role of various factors in renal disposition of digoxin through application of physiologically based kidney model to renal impairment populations","volume":"360","author":"Scotcher","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0047","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1111\/bcp.12685","article-title":"Physiologically-based pharmacokinetic modeling of renally excreted antiretroviral drugs in pregnant women","volume":"80","author":"De Sousa Mendes","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0048","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1124\/dmd.116.072066","article-title":"Abundance of drug transporters in the human kidney cortex as quantified by quantitative targeted proteomics","volume":"44","author":"Prasad","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0049","first-page":"285","article-title":"Proximal tubule characteristics of cultured human renal cortex epithelium","volume":"113","author":"Kempson","year":"1989","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0050","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/jps.24645","article-title":"Quantitative targeted absolute proteomics for 28 transporters in brush-border and basolateral membrane fractions of rat kidney","volume":"105","author":"Uchida","year":"2016","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0051","doi-asserted-by":"crossref","first-page":"F679","DOI":"10.1152\/ajprenal.2000.279.4.F679","article-title":"Localization of organic cation transporters OCT1 and OCT2 in rat kidney","volume":"279","author":"Karbach","year":"2000","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0052","doi-asserted-by":"crossref","first-page":"21366","DOI":"10.3390\/ijms151121366","article-title":"Small molecule membrane transporters in the mammalian podocyte: a pathogenic and therapeutic target","volume":"15","author":"Zennaro","year":"2014","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0053","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1002\/pmic.201500433","article-title":"Large-scale multiplex absolute protein quantification of drug-metabolizing enzymes and transporters in human intestine, liver, and kidney microsomes by SWATH-MS: Comparison with MRM\/SRM and HR-MRM\/PRM","volume":"16","author":"Nakamura","year":"2016","journal-title":"Proteomics"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0054","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1124\/dmd.111.043174","article-title":"Using expression data for quantification of active processes in physiologically based pharmacokinetic modeling","volume":"40","author":"Meyer","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0055","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1208\/s12248-016-9959-1","article-title":"Key to opening kidney for in vitro-in vivo extrapolation entrance in health and disease: part II: mechanistic models and in vitro-in vivo extrapolation","volume":"18","author":"Scotcher","year":"2016","journal-title":"AAPS J"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0056","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1208\/s12248-016-9942-x","article-title":"Key to opening kidney for in vitro\u2013in vivo extrapolation entrance in health and disease: part I: in vitro systems and physiological data","volume":"18","author":"Scotcher","year":"2016","journal-title":"AAPS J"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0057","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.fct.2016.03.017","article-title":"Predicting points of departure for risk assessment based on in vitro cytotoxicity data and physiologically based kinetic (PBK) modeling: the case of kidney toxicity induced by aristolochic acid I","volume":"92","author":"Abdullah","year":"2016","journal-title":"Food Chem Toxicol"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0058","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1124\/dmd.112.050294","article-title":"Application of a physiologically based pharmacokinetic model to assess propofol hepatic and renal glucuronidation in isolation: utility of in vitro and in vivo data","volume":"41","author":"Gill","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0059","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1124\/dmd.111.043984","article-title":"Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin","volume":"40","author":"Gill","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0060","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/toxsci\/kfx239","article-title":"Multiscale mathematical model of drug-induced proximal tubule injury: linking urinary biomarkers to epithelial cell injury and renal dysfunction","volume":"162","author":"Gebremichael","year":"2018","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0061","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1124\/dmd.113.055806","article-title":"Uptake carriers and oncology drug safety","volume":"42","author":"Sprowl","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0062","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/967826","article-title":"Pathophysiology of cisplatin-induced acute kidney injury","volume":"2014","author":"Ozkok","year":"2014","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0063","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/clpt.2011.330","article-title":"Associations between ABCC2 polymorphisms and cisplatin disposition and efficacy","volume":"91","author":"Sprowl","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0064","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1002\/jps.20073","article-title":"Volume of distribution at steady state for a linear pharmacokinetic system with peripheral elimination","volume":"93","author":"Berezhkovskiy","year":"2004","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0065","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1124\/jpet.111.180984","article-title":"Physiological and molecular characterization of aristolochic acid transport by the kidney","volume":"338","author":"Dickman","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0066","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1517\/17425255.2015.1069274","article-title":"Role of organic cation transporters in drug-drug interaction","volume":"11","author":"Koepsell","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"Suppl 7","key":"10.1016\/j.semnephrol.2018.12.006_bib0067","first-page":"S73","article-title":"Renal transporter-mediated drug-drug interactions: are they clinically relevant?","volume":"56","author":"Lepist","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0068","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1007\/s11095-016-2024-z","article-title":"Projecting ADME behavior and drug-drug interactions in early discovery and development: application of the extended clearance classification system","volume":"33","author":"El-Kattan","year":"2016","journal-title":"Pharm Res"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0069","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/0091270002239705","article-title":"Pharmacokinetics and renal effects of cidofovir with a reduced dose of probenecid in HIV-infected patients with cytomegalovirus retinitis","volume":"43","author":"Wolf","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0070","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1517\/17460441.2013.748744","article-title":"Strategies for the design of hepatoselective glucokinase activators to treat type 2 diabetes","volume":"8","author":"Pfefferkorn","year":"2013","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0071","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1124\/dmd.114.058032","article-title":"Toward a unified model of passive drug permeation II: the physiochemical determinants of unbound tissue distribution with applications to the design of hepatoselective glucokinase activators","volume":"42","author":"Ghosh","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0072","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1021\/jm2014887","article-title":"Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotini c acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus","volume":"55","author":"Pfefferkorn","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0073","doi-asserted-by":"crossref","first-page":"e97139","DOI":"10.1371\/journal.pone.0097139","article-title":"The hepatoselective glucokinase activator PF-04991532 ameliorates hyperglycemia without causing hepatic steatosis in diabetic rats","volume":"9","author":"Erion","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0074","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1124\/dmd.114.061218","article-title":"Comparison of the circulating metabolite profile of PF-04991532, a hepatoselective glucokinase activator, across preclinical species and humans: potential implications in metabolites in safety testing assessment","volume":"43","author":"Sharma","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0075","series-title":"Medical physiology: principles for clinical medicine.","first-page":"399","article-title":"Kidney function","author":"Tanner","year":"2013"},{"year":"1974","series-title":"Physiology of the kidney and body fluids: an introductory text","author":"Pitts","key":"10.1016\/j.semnephrol.2018.12.006_bib0076"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0077","series-title":"Vander's renal physiology. 8th ed","article-title":"Basic renal processes for sodium, chloride, and water","author":"Eaton","year":"2016"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0078","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/MNH.0b013e3283410a7d","article-title":"Glomerular number and size variability and risk for kidney disease","volume":"20","author":"Puelles","year":"2011","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0079","first-page":"177","article-title":"The excretion of water","volume":"23","author":"Smith","year":"1947","journal-title":"Bull N Y Acad Med"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0080","series-title":"Medical physiology: principles for clinical medicine.","first-page":"451","article-title":"Acid\u2013base homeostasis","author":"Tanner","year":"2013"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0081","first-page":"R3","article-title":"Structural organization of the renal medulla: comparative and functional aspects","volume":"241","author":"Kriz","year":"1981","journal-title":"Am J Physiol"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0082","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1208\/s12248-016-9942-x","article-title":"Key to opening kidney for in vitro-in vivo extrapolation entrance in health and disease: part I: in vitro systems and physiological data","volume":"18","author":"Scotcher","year":"2016","journal-title":"AAPS J"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0083","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/psp4.12101","article-title":"Predictive performance of physiologically based pharmacokinetic and population pharmacokinetic modeling of renally cleared drugs in children","volume":"5","author":"Zhou","year":"2016","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0084","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1161\/01.HYP.35.3.822","article-title":"Glomerular hyperfiltration in hypertensive African Americans","volume":"35","author":"Kotchen","year":"2000","journal-title":"Hypertension"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0085","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s40262-015-0253-7","article-title":"A physiologically based pharmacokinetic drug-disease model to predict carvedilol exposure in adult and paediatric heart failure patients by incorporating pathophysiological changes in hepatic and renal blood flows","volume":"54","author":"Rasool","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0086","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13293-015-0020-3","article-title":"Expression of drug transporters in human kidney: impact of sex, age, and ethnicity","volume":"6","author":"Joseph","year":"2015","journal-title":"Biol Sex Differ"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0087","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ejps.2017.05.055","article-title":"Prediction of renal transporter-mediated drug-drug interactions for a drug which is an OAT substrate and inhibitor using PBPK modelling","volume":"106","author":"Ball","year":"2017","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0088","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1124\/dmd.116.074294","article-title":"Quantitative prediction of human renal clearance and drug-drug interactions of organic anion transporter substrates using in vitro transport data: a relative activity factor approach","volume":"45","author":"Mathialagan","year":"2017","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0089","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/cts.12486","article-title":"Prediction of transporter-mediated drug-drug interactions for baricitinib","volume":"10","author":"Posada","year":"2017","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0090","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s13318-017-0418-x","article-title":"Physiologically based pharmacokinetic modelling and prediction of metformin pharmacokinetics in renal\/hepatic-impaired young adults and elderly populations","volume":"42","author":"Rhee","year":"2017","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0091","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1158\/1078-0432.CCR-14-0791","article-title":"Complex disease-, gene-, and drug-drug interactions: impacts of renal function, CYP2D6 phenotype, and OCT2 activity on veliparib pharmacokinetics","volume":"20","author":"Li","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semnephrol.2018.12.006_bib0092","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1124\/jpet.116.237438","article-title":"Delineating the role of various factors in renal disposition of digoxin through application of physiologically based kidney model to renal impairment populations","volume":"360","author":"Scotcher","year":"2017","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929518301852?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929518301852?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T23:33:45Z","timestamp":1759448025000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0270929518301852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":92,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S0270929518301852"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2018.12.006","relation":{},"ISSN":["0270-9295"],"issn-type":[{"type":"print","value":"0270-9295"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modeling Exposure to Understand and Predict Kidney Injury","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nephrology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semnephrol.2018.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}